C50
Conditions
Interventions
Group 1: Use of a digital home health care center (DHHC) and completion of questionnaires
Group 2: Completion of questionnaires
Sponsors
Frauenklinik des Uniklinikums Erlangen
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Diagnosis of hormone rezeptor positive breast cancer 2) Oral cancer therapy with CDK4/6 inhibitor, PARP inhibitor or Capeciabine as part of clinical routine 3) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Pace maker or implanted cardioverter-defibrillator (ICD) 2) Severe blood clotting disorder that required regular clotting checks 3) Abnormal ECG during last known control 4) Any other comirbidity that might interfere with study interventions or study participation (as per investigator's discretion) 5) Participation in other mHealth programms
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decreased leucocytes, detected by DHHC or during routine checkup at 1 week, 2 weeks, 3 weeks and 4 weeks of study participation | — |
Secondary
| Measure | Time frame |
|---|---|
| Prolongation of QTc intervall, detected by DHHC or during routine checkup at 1 week, 2 weeks, 3 weeks and 4 weeks of study participation | — |
Countries
Germany
Contacts
Public ContactPeter A. Fasching
Frauenklinik des Uniklinikums Erlangen
Outcome results
None listed